Repligen Corp (RGEN) stock
RGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 7/30136% above fair value
$163.81−6.48 (-3.81%)
Close on Nov 20, 2026Market cap $10.47BP/E –Yield –
Repligen shares outstanding
Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.
Repligen's shares outstanding was 57M at Sep 30, 2026. For fiscal 2025 it was 0M, up 1.1% from the year before. Over ten years it grew -47.2% a year on average. The highest annual figure on record is 49M in fiscal 2019.
Annual shares outstanding
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0M | +1.1% |
| FY2024 | Dec 31, 2024 | 0M | -0.8% |
| FY2023 | Dec 31, 2023 | 0M | -1.9% |
| FY2022 | Dec 31, 2022 | 0M | +0.3% |
| FY2021 | Dec 31, 2021 | 0M | +6.3% |
| FY2020 | Dec 31, 2020 | 0M | -99.9% |
| FY2019 | Dec 31, 2019 | 49M | +8.2% |
| FY2018 | Dec 31, 2018 | 45M | +16.1% |
| FY2017 | Dec 31, 2017 | 39M | +114712.8% |
| FY2016 | Dec 31, 2016 | 0M | -99.9% |
| FY2015 | Dec 31, 2015 | 34M | +0.9% |
| FY2014 | Dec 31, 2014 | 33M | +2.6% |
| FY2013 | Dec 31, 2013 | 32M | +5.3% |
| FY2011 | Mar 31, 2011 | 31M | +0.1% |
| FY2010 | Mar 31, 2010 | 31M | – |
Quarterly shares outstanding
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 57M | +0.0% |
| Q2 FY2026 | Jun 30, 2026 | 57M | +0.2% |
| Q1 FY2026 | Mar 31, 2026 | 57M | +0.2% |
| Q4 FY2025 | Dec 31, 2025 | 0M | +3.4% |
| Q3 FY2025 | Sep 30, 2025 | 57M | +100828.4% |
| Q2 FY2025 | Jun 30, 2025 | 57M | +100034.7% |
| Q1 FY2025 | Mar 31, 2025 | 57M | +99947.8% |
| Q4 FY2024 | Dec 31, 2024 | 0M | +0.2% |
| Q3 FY2024 | Sep 30, 2024 | 0M | -1.6% |
| Q2 FY2024 | Jun 30, 2024 | 0M | -0.7% |
| Q1 FY2024 | Mar 31, 2024 | 0M | -0.9% |
| Q4 FY2023 | Dec 31, 2023 | 0M | -4.1% |
| Q3 FY2023 | Sep 30, 2023 | 0M | -0.6% |
| Q2 FY2023 | Jun 30, 2023 | 0M | +0.2% |
| Q1 FY2023 | Mar 31, 2023 | 0M | -3.0% |
| Q4 FY2022 | Dec 31, 2022 | 0M | -1.4% |
| Q3 FY2022 | Sep 30, 2022 | 0M | -0.1% |
| Q2 FY2022 | Jun 30, 2022 | 0M | -0.1% |
| Q1 FY2022 | Mar 31, 2022 | 0M | +3.4% |
| Q4 FY2021 | Dec 31, 2021 | 0M | -99.9% |
| Q3 FY2021 | Sep 30, 2021 | 0M | -99.9% |
| Q2 FY2021 | Jun 30, 2021 | 0M | -99.9% |
| Q1 FY2021 | Mar 31, 2021 | 0M | -99.9% |
| Q3 FY2020 | Sep 30, 2020 | 53M | +3.2% |
| Q2 FY2020 | Jun 30, 2020 | 53M | +8.7% |
| Q1 FY2020 | Mar 31, 2020 | 53M | +14.8% |
| Q4 FY2019 | Dec 31, 2019 | 53M | +115624.0% |
| Q3 FY2019 | Sep 30, 2019 | 52M | +114990.2% |
| Q2 FY2019 | Jun 30, 2019 | 49M | +110568.4% |
| Q1 FY2019 | Mar 31, 2019 | 46M | +4.3% |
| Q3 FY2018 | Sep 30, 2018 | 0M | -99.9% |
| Q2 FY2018 | Jun 30, 2018 | 0M | -99.9% |
| Q1 FY2018 | Mar 31, 2018 | 0M | -99.9% |
| Q4 FY2017 | Dec 31, 2017 | 44M | +29.1% |
| Q3 FY2017 | Sep 30, 2017 | 43M | – |
| Q2 FY2017 | Jun 30, 2017 | 35M | – |
| Q1 FY2017 | Mar 31, 2017 | 34M | – |
| Q4 FY2016 | Dec 31, 2016 | 34M | – |
See a number that looks wrong?